JPH11514646A - クラリスロマイシンの水性粒状化方法 - Google Patents
クラリスロマイシンの水性粒状化方法Info
- Publication number
- JPH11514646A JPH11514646A JP9517384A JP51738497A JPH11514646A JP H11514646 A JPH11514646 A JP H11514646A JP 9517384 A JP9517384 A JP 9517384A JP 51738497 A JP51738497 A JP 51738497A JP H11514646 A JPH11514646 A JP H11514646A
- Authority
- JP
- Japan
- Prior art keywords
- granules
- clarithromycin
- granulation
- temperature
- carbomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. マクロライド系抗生物質の顆粒を製造する方法であって、次の工程即ち (a)マクロライド系抗生物質およびカルボマーを約1:10と約5:2の間の 重量比にて混合し、 (b)この混合物を水性溶媒で湿潤させ、 (c)この混合物をマクロライド系抗生物質−カルボマー顆粒が形成せしめられ るのに十分な時間ブレンドし、しかもこのブレンディングは、約0〜約70℃の 温度に維持されているヘッドスペースを有する容器中で達成され、そして (d)これらのマクロライド系抗生物質−カルボマー顆粒を乾燥する ことからなる上記方法。 2. カルボマーがアクリルポリマーである、請求項1に記載の方法。 3. カルボマーがカーボポール974Pアクリル酸ポリマーである、請求項2 に記載の方法。 4. 抗生物質マクロライドが、エリスロマイシンおよびクラ リスロマイシンから成る群から選択される、請求項1に記載の方法。 5. 抗生物質マクロライドがクラリスロマイシンである、請求項4に記載の方 法。 6. 工程(a)において形成される混合物が約1:10と約5:2の間の比率 のクラリスロマイシンおよびアクリルポリマーからなる、請求項2に記載の方法 。 7. 混合物が工程(b)において約1.5重量部と約2.5重量部の間の水で 湿潤される、請求項6に記載の方法。 8. 混合物が工程(b)において約1.5重量部と約2.5重量部の間の水で 湿潤される、請求項1に記載の方法。 9. 顆粒が主に40〜80メッシュ粒子から成る、請求項1に記載の方法。 10. 工程(d)に先立って、工程(c)において形成されたマクロライド系 抗生物質−カルボマー顆粒を結合剤の水溶液と混合する追加的工程を更に含む、 請求項1に記載の方法。 11. 結合剤がポリビニルピロリドンである、請求項10に記載の方法。 12. ヘッドスペース温度が水ジャケットにより維持される、 請求項1に記載の方法。 13. ヘッドスペース温度が約30〜約50℃の温度に維持される、請求項1 2に記載の方法。 14. ヘッドスペース温度が、水ジャケットの入口温度を約20〜約40℃に 維持することにより維持される、請求項13に記載の方法。 15. 請求項5の方法により製造された、クラリスロマイシンおよびカルボマ ーからなる製薬顆粒。 16. 請求項10の方法により製造された、クラリスロマイシンおよびカルボ マーからなる製薬顆粒。 17. マクロライド系抗生物質−カルボマーの製薬顆粒の硬度を増大する方法 であって、次の工程即ち (a)該顆粒を結合剤の水溶液と混合し、そして (b)これらの顆粒を乾燥する ことからなる上記方法。 18. 結合剤がポリビニルピロリドンである、請求項17に記載の方法。 19. クラリスロマイシンおよびカーボポール974Pアクリル酸ポリマーか らなる製薬顆粒の製造方法であって、次の工 程即ち (a)該クラリスロマイシンおよび該ポリマーを約5:2と約5:3の間の重量 比にて混合し、 (b)この混合物を約1.5重量部と約2.5重量部の間の水で湿潤させ、 (c)この混合物をクラリスロマイシン−カーボポール974P顆粒が形成せし められるのに十分な時間ブレンドし、しかもこのブレンディングは、約30〜約 50℃の温度に維持されているヘッドスペースを有する容器中で達成され、 (d)これらのクラリスロマイシン−カーボポール974P顆粒を、ポリビニル ピロリドンの水溶液を用いて再粒状化し、そして (e)これらのクラリスロマイシン−カーボポール974P顆粒を乾燥する ことからなる上記方法。 20. 請求項19の方法により製造されたクラリスロマイシン−カーボポール 974P顆粒からなる製薬製剤。 21. 顆粒が主に40〜80メッシュ粒子から成る、請求項10に記載の方法 。 22. 工程(b)の水性溶媒が有機溶媒を本質的に含まない、請求項1に記載 の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US715095P | 1995-11-01 | 1995-11-01 | |
US60/007,150 | 1995-11-01 | ||
US08/722,288 | 1996-10-09 | ||
US08/722,288 US5919489A (en) | 1995-11-01 | 1996-10-09 | Process for aqueous granulation of clarithromycin |
PCT/US1996/016794 WO1997016174A1 (en) | 1995-11-01 | 1996-10-18 | Process for aqueous granulation of clarithromycin |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11514646A true JPH11514646A (ja) | 1999-12-14 |
JP4334015B2 JP4334015B2 (ja) | 2009-09-16 |
Family
ID=26676595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51738497A Expired - Lifetime JP4334015B2 (ja) | 1995-11-01 | 1996-10-18 | クラリスロマイシンの水性粒状化方法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US5919489A (ja) |
EP (1) | EP0858324B1 (ja) |
JP (1) | JP4334015B2 (ja) |
KR (1) | KR100524202B1 (ja) |
AT (1) | ATE241963T1 (ja) |
AU (1) | AU706837B2 (ja) |
CA (1) | CA2235607C (ja) |
DE (1) | DE69628575T2 (ja) |
DK (1) | DK0858324T3 (ja) |
ES (1) | ES2200075T3 (ja) |
IL (1) | IL123571A (ja) |
PT (1) | PT858324E (ja) |
WO (1) | WO1997016174A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004537558A (ja) * | 2001-07-23 | 2004-12-16 | ビオアリヤンス・ファルマ | 持続放出性の生体粘着性治療システム |
JP5585920B2 (ja) * | 2010-12-27 | 2014-09-10 | 富田製薬株式会社 | 粒子状製剤 |
WO2020032159A1 (ja) * | 2018-08-10 | 2020-02-13 | 日本臓器製薬株式会社 | 粒状組成物及びその製造方法 |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6551616B1 (en) | 1997-04-11 | 2003-04-22 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
US6010718A (en) * | 1997-04-11 | 2000-01-04 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
IN191239B (ja) | 1999-06-11 | 2003-10-11 | Ranbaxy Lab Ltd | |
AU4943000A (en) * | 1999-06-11 | 2001-01-02 | Ranbaxy Laboratories Limited | Taste masked compositions |
AU1169601A (en) * | 1999-11-16 | 2001-05-30 | Ranbaxy Laboratories Limited | Taste masked oral compositions |
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
CA2401571A1 (en) * | 2000-02-29 | 2001-09-07 | Ilya Avrutov | Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same |
US20030099715A1 (en) * | 2000-03-28 | 2003-05-29 | Schwarz Franz Xaver | Granulated particles with masked taste |
US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
DE10133546A1 (de) * | 2001-07-11 | 2003-03-06 | Petra Bastian | Mischkomplexe zur Maskierung bitter schmeckender Substanzen |
EP1411899B1 (en) * | 2001-08-01 | 2009-03-11 | Novartis AG | Taste masking composition |
US20040043073A1 (en) * | 2002-06-14 | 2004-03-04 | Chih-Ming Chen | Pharmaceutical compositions for drugs having pH-dependent solubility |
US20060083759A1 (en) * | 2002-07-17 | 2006-04-20 | Aleksander Resman | Stabilization of the profile of release of active substances from a formulation |
EP1417958A1 (en) * | 2002-11-08 | 2004-05-12 | Pari GmbH | Wet granulation process |
PL1638529T3 (pl) * | 2003-06-16 | 2017-03-31 | Andrx Pharmaceuticals, Llc. | Kompozycja doustna o przedłużonym uwalnianiu |
EP1648407A4 (en) | 2003-07-21 | 2011-08-31 | Middlebrook Pharmaceuticals Inc | ANTIBIOTIC PRODUCT, CORRESPONDING USE AND FORMULATION |
JP2006528189A (ja) | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質産物、その使用法および製剤 |
WO2005009364A2 (en) | 2003-07-21 | 2005-02-03 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
EP1653925A1 (en) | 2003-08-11 | 2006-05-10 | Advancis Pharmaceutical Corporation | Robust pellet |
JP2007502294A (ja) | 2003-08-12 | 2007-02-08 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
EP1658034A4 (en) | 2003-08-29 | 2011-06-22 | Middlebrook Pharmaceuticals Inc | ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION |
CA2538064C (en) | 2003-09-15 | 2013-12-17 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
BRPI0417348A (pt) * | 2003-12-04 | 2007-03-13 | Pfizer Prod Inc | processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo |
BRPI0416534A (pt) * | 2003-12-04 | 2007-01-09 | Pfizer Prod Inc | composições multiparticuladas com estabilidade melhorada |
WO2005053653A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride |
WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
BRPI0417338A (pt) * | 2003-12-04 | 2007-04-17 | Pfizer Prod Inc | formas de dosagem de azitromicina multiparticulada por processos a base de lìquido |
PT1691787E (pt) * | 2003-12-04 | 2008-09-02 | Pfizer Prod Inc | Método de formação de multipartículas farmacêuticas |
US7943585B2 (en) | 2003-12-22 | 2011-05-17 | Sandoz, Inc. | Extended release antibiotic composition |
WO2006014427A1 (en) | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
CN1883456B (zh) * | 2005-06-20 | 2010-12-15 | 常州市第四制药厂有限公司 | 掩味药物颗粒及其制备方法和用途 |
EP1904041A2 (en) * | 2005-07-07 | 2008-04-02 | Elan Pharma International Limited | Nanoparticulate clarithromycin formulations |
US20070048364A1 (en) * | 2005-08-04 | 2007-03-01 | Yingxu Peng | Free flowing granules containing carbomer |
US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
EP1837020A1 (en) | 2006-03-24 | 2007-09-26 | Bioalliance Pharma | Mucosal bioadhesive slow release carrier for delivering active principles |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
US20070286903A1 (en) * | 2006-06-13 | 2007-12-13 | Becicka Brian T | Composition and method for taste masking |
EP2030613A1 (en) * | 2007-08-17 | 2009-03-04 | Abbott GmbH & Co. KG | Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics |
CN102813633A (zh) * | 2011-06-10 | 2012-12-12 | 塔科敏斯基制药厂波尔法合资公司 | 用湿法制粒制备包含大环内酯类抗生素的药物组合物的方法 |
RU2692469C1 (ru) * | 2018-06-25 | 2019-06-25 | ООО "Новые Антибиотики" | Лекарственное средство для лечения и предупреждения возникновения осложнений, связанных с химиотерапией и рентгенотерапией, а также состояний, связанных с повышенной проницаемостью кишки |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4608278A (en) * | 1983-06-22 | 1986-08-26 | The Ohio State University Research Foundation | Small particule formation and encapsulation |
US4808411A (en) * | 1987-06-05 | 1989-02-28 | Abbott Laboratories | Antibiotic-polymer compositions |
-
1996
- 1996-10-09 US US08/722,288 patent/US5919489A/en not_active Expired - Lifetime
- 1996-10-18 DE DE69628575T patent/DE69628575T2/de not_active Expired - Lifetime
- 1996-10-18 DK DK96937699T patent/DK0858324T3/da active
- 1996-10-18 PT PT96937699T patent/PT858324E/pt unknown
- 1996-10-18 AU AU75176/96A patent/AU706837B2/en not_active Expired
- 1996-10-18 IL IL12357196A patent/IL123571A/xx not_active IP Right Cessation
- 1996-10-18 AT AT96937699T patent/ATE241963T1/de active
- 1996-10-18 CA CA002235607A patent/CA2235607C/en not_active Expired - Lifetime
- 1996-10-18 WO PCT/US1996/016794 patent/WO1997016174A1/en active IP Right Grant
- 1996-10-18 JP JP51738497A patent/JP4334015B2/ja not_active Expired - Lifetime
- 1996-10-18 EP EP96937699A patent/EP0858324B1/en not_active Expired - Lifetime
- 1996-10-18 KR KR1019980703233A patent/KR100524202B1/ko not_active IP Right Cessation
- 1996-10-18 ES ES96937699T patent/ES2200075T3/es not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004537558A (ja) * | 2001-07-23 | 2004-12-16 | ビオアリヤンス・ファルマ | 持続放出性の生体粘着性治療システム |
JP4657603B2 (ja) * | 2001-07-23 | 2011-03-23 | ビオアリヤンス・ファルマ | 持続放出性の生体粘着性治療システム |
JP5585920B2 (ja) * | 2010-12-27 | 2014-09-10 | 富田製薬株式会社 | 粒子状製剤 |
WO2020032159A1 (ja) * | 2018-08-10 | 2020-02-13 | 日本臓器製薬株式会社 | 粒状組成物及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
PT858324E (pt) | 2003-10-31 |
DE69628575D1 (de) | 2003-07-10 |
EP0858324B1 (en) | 2003-06-04 |
CA2235607A1 (en) | 1997-05-09 |
ES2200075T3 (es) | 2004-03-01 |
US5919489A (en) | 1999-07-06 |
JP4334015B2 (ja) | 2009-09-16 |
EP0858324A1 (en) | 1998-08-19 |
KR19990067265A (ko) | 1999-08-16 |
IL123571A0 (en) | 1998-10-30 |
ATE241963T1 (de) | 2003-06-15 |
KR100524202B1 (ko) | 2006-07-06 |
DE69628575T2 (de) | 2004-04-29 |
IL123571A (en) | 2005-07-25 |
WO1997016174A1 (en) | 1997-05-09 |
DK0858324T3 (da) | 2003-09-29 |
CA2235607C (en) | 2003-05-13 |
MX9803480A (es) | 1998-09-30 |
AU7517696A (en) | 1997-05-22 |
AU706837B2 (en) | 1999-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11514646A (ja) | クラリスロマイシンの水性粒状化方法 | |
US5474989A (en) | Drug composition | |
NO176125B (no) | Fremgangsmåte for fremstilling av granulater for orale multipartikkelblandinger med kontrollert frigjöring | |
WO2000003735A1 (fr) | Excipient | |
JP2008540644A (ja) | 新規粒質化方法及びそれから生成される粒質物 | |
JP2004500193A (ja) | 顆粒剤の連続的製造方法 | |
JP2840132B2 (ja) | S(+)−イブプロフェン粒子の製造方法 | |
MX2007005427A (es) | Composicion de dispersion solida de pranlukast con biodisponibilidad mejorada y metodo para preparar la dispersion solida. | |
JP3368898B1 (ja) | 分岐鎖アミノ酸含有顆粒の製造方法 | |
WO1996041628A1 (fr) | Granules contenant du pranlukast, procede de production des granules et procede de reduction de la cohesion du pranlukast | |
JPH05320045A (ja) | 錠剤に直接圧縮可能な医薬粉末組成物を製造するための噴霧乾燥法 | |
CA2730005C (en) | High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms | |
JP5515943B2 (ja) | 分岐鎖アミノ酸を含有する顆粒、およびその製造方法 | |
US9693960B2 (en) | Method of controlling the release of an active ingredient from a dosage form | |
JPH0959156A (ja) | プランルカストを含有する造粒物、その製造方法およびプランルカストの付着凝集性改善方法 | |
JP2003116966A (ja) | 直接錠剤化用調合物および補助剤の調合方法 | |
EP0443027B1 (en) | Drug composition | |
WO2004110448A1 (ja) | 塩酸ベニジピン含有医薬組成物 | |
JPS63112519A (ja) | ニフエジピン製剤の製造方法 | |
CA2782498A1 (en) | Tablet composition containing kampo medicinal extract and its manufacturing process | |
MXPA98003480A (en) | Procedure for granulation in claritromycin wet | |
JP3682453B2 (ja) | 分岐鎖アミノ酸含有医薬用顆粒製剤の製造方法 | |
JPH053759A (ja) | 飼料添加物用コリスチン製剤 | |
JPH11255645A (ja) | テトラヒドロリプスタチン含有組成物 | |
JP2000072660A (ja) | 凍結解凍造粒法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060718 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061018 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080610 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080905 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20081211 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090428 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090501 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090609 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090623 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120703 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130703 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |